What is Retatrutide?

Retatrutide is an experimental drug triple-hormone receptor agonist. It works by stimulating three key metabolic hormone pathways at the same time:

1. GLP-1 (Glucagon-like peptide-1) → reduces appetite, slows stomach emptying, improves insulin sensitivity.

2. GIP (Glucose-dependent insulinotropic polypeptide) → helps regulate blood sugar and enhances the effect of GLP-1.

3. Glucagon receptor → increases energy expenditure, fat burning, and reduces liver fat.

This combination is designed to give stronger weight loss and metabolic improvements than current single- or dual-hormone drugs.

What Have Clinical Trials Shown?

Phase 2 Obesity Trials (non-diabetic participants)

• Participants received weekly injections of different doses (1 mg up to 12 mg).

• After 48 weeks:

  • People on the highest doses (8 mg and 12 mg) lost around 23–24% of their body weight on average.

  • By comparison, placebo groups lost almost no weight.

• Many participants also saw huge reductions in liver fat (up to 80–90%), making it potentially useful for people with fatty liver disease.

• Waist circumference, cholesterol levels, and insulin resistance also improved significantly.

Phase 2 Diabetes Trials (type 2 diabetes participants)

• People with type 2 diabetes lost 15–17% of their body weight on higher doses, which is much more than typical diabetes drugs achieve.

• Their blood sugar control (HbA1c) also improved by more than 2 percentage points in many cases.

• Cardiometabolic risk factors like blood pressure and triglycerides improved too.

Benefits Seen So Far

1. High levels of weight loss – more than semaglutide (Ozempic/Wegovy) and even more than tirzepatide (Mounjaro/Zepbound).

2. Liver health benefits – strong reductions in liver fat make it promising for fatty liver disease.

3. Diabetes improvements – better blood sugar control, insulin sensitivity, and metabolic health.

4. Wide metabolic effects – not just weight loss, but also reductions in waist size, cholesterol, and blood pressure.

Risks and Side Effects

Like other GLP-1 based drugs, retatrutide has digestive side effects, mostly:

• Nausea

• Vomiting

• Diarrhea

• Constipation

These side effects are more common at higher doses but are usually manageable.

Other considerations:

• Long-term safety is still unknown. So far, trials are under 1 year; we don’t know what happens with 3–5 years of use.

• Weight regain may occur if treatment is stopped, as seen with other weight-loss drugs.

• Because glucagon receptor activation raises energy expenditure, there may be unique side effects not fully understood yet.

How Does It Compare to Other Weight-Loss Drugs?

• Semaglutide (Ozempic/Wegovy) → typically produces 15% weight loss.

• Tirzepatide (Mounjaro/Zepbound) → usually 20–22% weight loss.

• Retatrutide → so far, the highest average weight loss recorded in clinical trials: 23–24% in obesity trials.

This means it could become the most powerful weight-loss medication available, if Phase 3 trials confirm the results.

Availability and Status

• Retatrutide is still in clinical trials (Phase 2 completed, Phase 3 ongoing).

• It is not yet approved by the FDA, EMA, or other regulatory agencies.

• If Phase 3 results are positive, approval could happen around 2026–2027.

Final Takeaway

Retatrutide looks like one of the most promising drugs for obesity and metabolic disease so far:

• Very strong weight loss results (comparable to bariatric surgery levels for some patients).

• Improves diabetes control, fatty liver, and heart risk factors.

• Not yet available outside trials, and long-term safety is still being studied.

It could become a game-changer in obesity treatment, but we need to see final Phase 3 data before it reaches the public.

Comparison Table: Retatrutide vs Ozempic vs Mounjaro